Name
University of Phoenix
NSG/507 Social Justice and Information Systems for Population Health
Prof. Name
Date
George Garcia is a 48-year-old man with type 2 diabetes mellitus (T2DM), hypertension, hyperlipidemia, and persistent ACE inhibitor-induced cough. His current blood pressure, HbA1c, and lipid levels indicate that his chronic conditions are not optimally controlled despite medication adherence. An appropriate evidence-based plan includes replacing lisinopril with an angiotensin II receptor blocker (ARB) such as losartan, continuing metformin and considering a GLP-1 receptor agonist for additional glycemic and cardiovascular benefits, initiating appropriate statin therapy, and developing realistic lifestyle interventions that accommodate his work as a long-haul truck driver. Regular blood pressure, laboratory, and metabolic monitoring is essential to reduce his long-term cardiovascular, renal, and metabolic risk.
George Garcia is a 48-year-old Hispanic male who presents for a routine three-month follow-up to review laboratory results and assess management of his chronic health conditions.
His medical history includes:
Type 2 diabetes mellitus
Hypertension
Erectile dysfunction
George also has a strong family history of cardiometabolic disease. His father has type 2 diabetes and a history of myocardial infarction, while his mother has type 2 diabetes and obesity. Both of his sisters have obesity. This family history, combined with George’s diabetes, hypertension, dyslipidemia, overweight BMI, and sedentary occupation, increases his long-term cardiovascular risk.
| Family Member | Relevant Medical History |
|---|---|
| Father | Type 2 diabetes and myocardial infarction |
| Mother | Type 2 diabetes and obesity |
| Two sisters | Obesity |
George works as an interstate truck driver, which creates practical barriers to maintaining a healthy lifestyle. His long periods of sitting limit physical activity, while frequent fast-food meals make it difficult to maintain a heart-healthy and diabetes-friendly diet. He reports drinking approximately three cups of coffee and two beers daily and getting minimal regular exercise.
Importantly, George reports that he takes his prescribed medications consistently. He previously declined statin therapy because of concerns about adverse effects but is now willing to begin cholesterol-lowering treatment.
George’s clinical findings demonstrate persistent hypertension, suboptimal glycemic control, and significant dyslipidemia.
| Measurement | Result |
|---|---|
| Blood pressure | 142/90 mmHg |
| Pulse | 82 beats/min |
| Respiratory rate | 20 breaths/min |
| BMI | 28 kg/m² |
A BMI of 28 kg/m² falls within the overweight range. His blood pressure of 142/90 mmHg is above the recommended treatment goal for most adults with diabetes.
| Test | Result |
|---|---|
| HbA1c | 7.5% |
| Fasting glucose | 116 mg/dL |
George’s HbA1c of 7.5% is above the commonly used treatment goal of less than 7% for many nonpregnant adults with diabetes, although individualized targets should be determined based on the patient’s overall clinical circumstances.
| Test | Result |
|---|---|
| eGFR | 110 mL/min/1.73 m² |
| Creatinine | 0.9 mg/dL |
| Urine albumin-to-creatinine ratio | Normal |
His normal kidney function and normal urine albumin-to-creatinine ratio are reassuring. However, continued monitoring is important because both diabetes and hypertension can contribute to chronic kidney disease over time.
| Lipid | Result |
|---|---|
| Total cholesterol | 235 mg/dL |
| LDL cholesterol | 180 mg/dL |
| HDL cholesterol | 32 mg/dL |
| Triglycerides | 190 mg/dL |
The lipid profile demonstrates significant dyslipidemia, particularly the LDL cholesterol of 180 mg/dL and low HDL cholesterol of 32 mg/dL.
George currently takes:
Metformin XR 2,000 mg daily
Lisinopril 40 mg daily
Sildenafil 100 mg as needed
Additional clinical findings include a reported 10-year ASCVD risk of approximately 5%, no evidence of diabetic retinopathy, a normal foot examination, and a persistent dry cough.
George’s blood pressure is 142/90 mmHg despite taking lisinopril 40 mg daily. Under the ACC/AHA blood pressure classification system, this reading falls within stage 2 hypertension. Because George also has diabetes, maintaining good blood pressure control is particularly important for reducing his risk of cardiovascular disease and diabetic kidney disease.
The persistent dry cough that developed after lisinopril therapy is highly consistent with an ACE inhibitor-associated cough. ACE inhibitors can increase bradykinin concentrations, which may trigger a persistent, nonproductive cough.
Because George is experiencing a persistent ACE inhibitor-associated cough, switching to an ARB is a reasonable treatment strategy.
The proposed medication change is:
Discontinue lisinopril 40 mg daily.
Initiate losartan 50 mg orally once daily.
Reassess blood pressure and tolerance after initiation.
Losartan blocks the angiotensin II receptor and provides antihypertensive and renoprotective effects without the same bradykinin accumulation associated with ACE inhibitors.
The goal is not simply to change medications but to maintain effective blood pressure management while removing an adverse effect that could eventually interfere with adherence.
Losartan is an appropriate alternative because it can:
Lower blood pressure effectively.
Provide renin-angiotensin system blockade in a patient with diabetes.
Avoid the ACE inhibitor-associated cough mechanism.
Support continued medication adherence when an ACE inhibitor is not tolerated.
Potential adverse effects include dizziness, hypotension, and hyperkalemia. Changes in renal function can also occur, particularly in patients with underlying kidney disease or other risk factors.
George should have his blood pressure reassessed after initiating the new medication. Serum creatinine and potassium should also be monitored after starting or changing renin-angiotensin system therapy.
A practical monitoring plan includes:
Home blood pressure monitoring.
Serum potassium and creatinine after medication initiation.
Assessment for dizziness or symptomatic hypotension.
Follow-up within several weeks to determine whether additional antihypertensive therapy is needed.
If blood pressure remains above the individualized treatment goal, an additional antihypertensive agent may be considered rather than simply increasing losartan indefinitely.
George’s occupation makes conventional lifestyle recommendations difficult to maintain. Instead of recommending an unrealistic exercise or diet plan, interventions should be designed around his driving schedule.
The Dietary Approaches to Stop Hypertension (DASH) eating pattern emphasizes vegetables, fruits, whole grains, low-fat dairy products, lean proteins, and foods lower in saturated fat and sodium.
For a long-haul truck driver, this does not require eliminating restaurant meals entirely. George can make gradual substitutions, such as choosing grilled rather than fried foods, selecting vegetables or fruit when available, and limiting highly processed foods.
Reducing sodium is particularly important for blood pressure management. George can reduce sodium exposure by:
Limiting processed meats and packaged snacks.
Choosing lower-sodium options when available.
Reading nutrition labels.
Limiting heavily salted restaurant foods.
Choosing fresh or minimally processed foods when possible.
Practical options for George include grilled chicken, salads with dressing on the side, fruit, nuts in appropriate portions, whole-grain options, and water or unsweetened beverages.
Preparing food before long trips can make healthy eating easier and reduce reliance on fast food.
George does not need a traditional gym routine to become more active. He can incorporate short periods of movement into scheduled driving breaks. Walking for several minutes during breaks, performing simple resistance exercises, and increasing daily steps can help reduce sedentary time.
The long-term goal should be to work toward recommended levels of moderate-intensity physical activity while considering his schedule and physical capabilities.
George reports drinking approximately two beers each day. Reducing alcohol intake may benefit blood pressure, metabolic health, and overall cardiovascular risk.
His coffee consumption should also be discussed in the context of his blood pressure and sleep. Unsweetened coffee can be preferable to sugar-sweetened beverages, but excessive caffeine should be avoided if it contributes to elevated blood pressure, palpitations, or sleep problems.
Garlic supplements should not be presented as a primary treatment for George’s hypertension or dyslipidemia. Although some research suggests modest effects on cardiovascular risk factors, supplements do not replace evidence-based antihypertensive or lipid-lowering medications and may interact with other therapies.
George’s HbA1c is 7.5% despite taking metformin XR 2,000 mg daily. This suggests that additional treatment may be appropriate if his individualized glycemic target is not being achieved.
His sedentary lifestyle, frequent fast-food consumption, overweight BMI, and strong family history may contribute to difficulty achieving optimal glycemic control.
His normal eGFR and urine albumin-to-creatinine ratio indicate that there is currently no evidence of significant diabetic kidney impairment based on the provided results.
Continuing metformin while adding a GLP-1 receptor agonist such as liraglutide is a reasonable option when additional glucose lowering and weight-related benefits are desired.
GLP-1 receptor agonists can improve glycemic control by enhancing glucose-dependent insulin secretion, reducing inappropriate glucagon secretion, slowing gastric emptying, and increasing satiety. Some agents in this class have also demonstrated cardiovascular benefits in patients with T2DM and elevated cardiovascular risk.
For George, these effects may be particularly useful because he has diabetes, overweight status, hypertension, and significant dyslipidemia.
The specific medication and dose should be individualized based on contraindications, tolerability, cost, insurance coverage, cardiovascular and kidney status, and current diabetes treatment goals.
Potential benefits include:
Improved HbA1c.
Reduced appetite and body weight.
Low intrinsic risk of hypoglycemia when used without insulin or insulin-secretagogue therapy.
Cardiovascular risk reduction with certain agents in appropriate populations.
Gastrointestinal effects are the most common adverse effects and may include:
Nausea
Vomiting
Diarrhea
Constipation
Abdominal discomfort
Starting at a low dose and gradually increasing the dose according to the specific medication’s prescribing information can improve tolerability.
Liraglutide and certain other GLP-1 receptor agonists carry a boxed warning regarding thyroid C-cell tumors based on animal studies. They should not be used in patients with a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2.
Other precautions should be assessed before treatment, including a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, and other medication-specific contraindications.
George should return for ongoing diabetes assessment and medication adjustment. HbA1c is generally reassessed approximately every three months when treatment has recently changed or when the patient is not at goal.
Monitoring should include:
HbA1c.
Weight and BMI.
Renal function.
Medication tolerance.
Cardiovascular risk factors.
Blood pressure.
Appropriate diabetes complication screening.
Home glucose monitoring may be useful depending on his treatment regimen and clinical needs, although routine frequent monitoring is not always necessary for patients with T2DM who are not using insulin or medications that cause hypoglycemia.
George’s lifestyle plan should focus on changes he can realistically maintain while traveling.
He can improve diabetes management by preparing meals and snacks before long trips, choosing high-fiber carbohydrates, increasing vegetables and lean protein, limiting sugar-sweetened beverages, reducing alcohol, and walking during scheduled breaks.
Replacing refined carbohydrates with higher-fiber alternatives can improve overall dietary quality. Portion control is also important because restaurant meals can contain large amounts of calories, sodium, refined carbohydrates, and saturated fat.
George’s LDL cholesterol is 180 mg/dL, HDL cholesterol is 32 mg/dL, and triglycerides are 190 mg/dL. This pattern represents significant dyslipidemia and adds to his cardiovascular risk.
Although his reported 10-year ASCVD risk is approximately 5%, that number should not be considered in isolation. Diabetes, markedly elevated LDL cholesterol, hypertension, overweight status, low HDL cholesterol, and a strong family history all contribute to his overall risk profile.
An LDL level of 180 mg/dL is below the ≥190 mg/dL threshold that is typically treated as severe primary hypercholesterolemia, but it is still sufficiently elevated to warrant intensive risk-factor management.
Because George is 48 years old and has diabetes, statin therapy is recommended as part of cardiovascular risk reduction. Given his markedly elevated LDL cholesterol and multiple cardiovascular risk factors, a high-intensity statin is a reasonable treatment choice if he tolerates it and has no contraindication.
A reasonable option is:
Atorvastatin 40 mg orally once daily.
Atorvastatin inhibits HMG-CoA reductase, an enzyme involved in hepatic cholesterol synthesis, thereby increasing hepatic LDL receptor activity and reducing circulating LDL cholesterol.
Rosuvastatin 20–40 mg daily is another high-intensity option.
Statins can also be broadly categorized according to their physicochemical properties.
| More Hydrophilic Statins | More Lipophilic Statins |
|---|---|
| Rosuvastatin | Atorvastatin |
| Pravastatin | Simvastatin |
These classifications may be useful when discussing statin tolerability, although they do not by themselves determine which statin is best for an individual patient.
Most patients tolerate statins well. Possible adverse effects include muscle symptoms and mild elevations in liver enzymes.
George previously declined statin therapy because of concerns about adverse effects. Patient education is therefore important. Explaining the expected benefits, addressing misconceptions, and discussing what to do if muscle symptoms occur can improve acceptance and adherence.
Severe muscle pain, marked weakness, or dark-colored urine requires prompt medical evaluation because these symptoms can indicate severe muscle injury, although rhabdomyolysis is rare.
A lipid panel should generally be repeated about 4–12 weeks after starting or changing statin therapy to evaluate adherence and response. Subsequent lipid monitoring can be performed periodically based on treatment response and clinical circumstances.
Routine liver enzyme testing is not required at every visit but should be obtained when clinically indicated and according to current prescribing recommendations.
George’s management should address all major cardiovascular and metabolic risk factors rather than treating each abnormal laboratory result independently.
The priority interventions are:
Replace lisinopril with losartan because of persistent ACE inhibitor-associated cough.
Continue metformin while considering a GLP-1 receptor agonist for additional glycemic and weight-related benefits.
Initiate high-intensity statin therapy, such as atorvastatin 40 mg daily, given his diabetes and substantially elevated LDL cholesterol.
Develop a DASH-style, lower-sodium eating pattern that is practical for a truck driver.
Increase physical activity through walking and movement during scheduled breaks.
Reduce alcohol consumption.
Monitor blood pressure at home.
Continue appropriate diabetes monitoring.
Reassess lipid levels after initiating statin therapy.
Monitor renal function and serum potassium after changing ARB therapy.
Follow-up is essential because medication changes should be evaluated based on both effectiveness and tolerability.
After switching to losartan, George should have blood pressure, renal function, and potassium monitored. If blood pressure remains above the individualized target, additional therapy may be necessary.
After adding or changing diabetes medication, HbA1c should be reassessed at an appropriate interval, generally around three months when glycemic control is not at goal.
After starting atorvastatin, a lipid panel should be obtained approximately 4–12 weeks later to determine the LDL response and assess adherence.
George should also receive counseling about the warning signs of medication adverse effects and should be encouraged to discuss barriers to treatment rather than discontinuing medications independently.
George’s case demonstrates why chronic disease management should be individualized according to the patient’s clinical findings, cardiovascular risk, medication tolerance, occupation, and lifestyle.
His persistent cough makes an ARB such as losartan a logical alternative to lisinopril. His HbA1c of 7.5% suggests that additional diabetes therapy may be appropriate, with a GLP-1 receptor agonist being one potential option. His LDL cholesterol of 180 mg/dL and diabetes warrant statin therapy, and his multiple risk factors make high-intensity treatment reasonable if tolerated.
Lifestyle counseling should be practical rather than generic. For a long-haul truck driver, healthier restaurant choices, meal preparation, walking during breaks, sodium reduction, and limiting alcohol may be more sustainable than unrealistic recommendations that do not account for his work environment.
A persistent, nonproductive cough is a recognized adverse effect of ACE inhibitors such as lisinopril. ACE inhibition can increase bradykinin and other mediators that contribute to cough. If the cough is troublesome, switching to an ARB such as losartan is commonly considered.
Losartan provides angiotensin II receptor blockade and can effectively lower blood pressure without the same bradykinin-mediated cough associated with ACE inhibitors. The switch is particularly reasonable when the cough is persistent and bothersome.
Yes. Under ACC/AHA classifications, 142/90 mmHg falls within stage 2 hypertension. In a patient with diabetes, blood pressure should be managed according to an individualized treatment goal, with many guidelines supporting a target below 130/80 mmHg when it can be safely achieved.
Metformin can remain an important component of T2DM therapy when it is tolerated and not contraindicated. When additional glycemic control is needed, another glucose-lowering medication can be added rather than automatically discontinuing metformin.
A GLP-1 receptor agonist can improve glycemic control and may promote weight loss. Certain agents, including liraglutide, have demonstrated cardiovascular benefits in appropriate patients with T2DM and cardiovascular risk.
His LDL of 180 mg/dL is markedly elevated, and he also has diabetes and several additional cardiovascular risk factors. Adults with diabetes in George’s age group generally benefit from statin therapy, and a high-intensity statin is reasonable when cardiovascular risk is sufficiently elevated and the medication is tolerated.
No. An LDL cholesterol level of 190 mg/dL or higher is generally classified as severe primary hypercholesterolemia and carries specific treatment recommendations. George’s LDL of 180 mg/dL does not cross that threshold, but it remains substantially elevated and requires aggressive cardiovascular risk management.
The most practical changes include preparing meals before trips, choosing lower-sodium and grilled foods at restaurants, replacing sugar-sweetened beverages with water or unsweetened drinks, walking during scheduled breaks, reducing alcohol intake, and limiting highly processed foods.
A repeat lipid panel is generally recommended approximately 4–12 weeks after starting or adjusting statin therapy. Further testing can then be scheduled periodically based on his response and treatment plan.
Blood pressure, serum creatinine, and potassium should be monitored after initiating losartan. George should also be assessed for dizziness, hypotension, or other adverse effects.
The George Garcia case illustrates the importance of an integrated approach to hypertension, type 2 diabetes, and dyslipidemia. His persistent ACE inhibitor-associated cough supports switching from lisinopril to losartan. His HbA1c of 7.5% despite metformin therapy indicates that additional diabetes treatment may be appropriate, and a GLP-1 receptor agonist is one evidence-based option. His LDL cholesterol of 180 mg/dL, diabetes, hypertension, and additional cardiovascular risk factors support initiating statin therapy, with high-intensity treatment being a reasonable choice when clinically appropriate.
The most effective plan also recognizes George’s occupational barriers. Sustainable dietary changes, increased movement during driving breaks, reduced sodium and alcohol intake, medication adherence, and scheduled laboratory monitoring can help improve long-term outcomes. Treatment should be individualized and reassessed regularly rather than relying on a single laboratory value or risk score.
American Diabetes Association Professional Practice Committee. (2025). Standards of care in diabetes—2025. Diabetes Care, 48(Supplement_1). https://diabetesjournals.org/care/issue/48/Supplement_1
American Diabetes Association Professional Practice Committee. (2025). Cardiovascular disease and risk management: Standards of care in diabetes—2025. Diabetes Care, 48(Supplement_1). https://doi.org/10.2337/dc25-S010
American College of Cardiology & American Heart Association. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13–e115. https://doi.org/10.1161/HYP.0000000000000065
Grundy, S. M., Stone, N. J., Bailey, A. L., et al. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation, 139(25), e1082–e1143. https://doi.org/10.1161/CIR.0000000000000625
Mayo Clinic. (2024). Statin side effects: Weigh the benefits and risks. https://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/in-depth/statin-side-effects
National Center for Complementary and Integrative Health. (2024). Garlic. U.S. Department of Health and Human Services, National Institutes of Health. https://www.nccih.nih.gov/health/garlic
U.S. National Library of Medicine. (2024). Losartan potassium: Drug information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/
U.S. National Library of Medicine. (2024). Liraglutide injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/
Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13–e115. https://doi.org/10.1161/HYP.0000000000000065
